Bayer stock trades below Xetra close as pharma outlook holds

Bayer stock traded at 55.36 euros on Lang & Schwarz at 17:01 CET on Friday, November 6, 2026, 1.53 percent below the Xetra close of Thursday, November 5, at 56.22 euros. The quote was 1.37 percent above the 54.61-euro level in the previous report from Friday morning, giving the second main stock-values edition a fresh market signal.

Pharma supports the earnings profile

Bayer entered the final quarter with a stronger pharmaceutical outlook after reporting third-quarter results on Tuesday, November 3. The company raised its 2026 target for the Pharmaceuticals EBITDA margin before special items to 25 to 27 percent from 23 to 25 percent previously.

The group also lifted its currency-adjusted 2026 EBITDA forecast to 9.8 billion euros to 10.3 billion euros, compared with 9.6 billion euros to 10.1 billion euros before. Bayer's investor-relations agenda lists the third-quarter 2026 results and covers the Crop Science, Pharmaceuticals and Consumer Health divisions.

Bayer Investor Relations presents the company’s reporting framework and current investment case. The revised targets improve the operating profile, but they do not remove the pressure from litigation payments, negative cash flow and patent-related declines in established medicines.

Trading signal remains mixed

The Friday move from the morning quote shows that the stock recovered during the session, while the latest price still stood below the previous Xetra close. That combination leaves execution in product launches, cost control, legal containment and debt reduction as key considerations for investors.

For live monitoring, investors can use the real-time quote of Bayer stock.

Investors can follow broader market developments in the current DAX market reports.

More news and analysis is available in further reports and analysis on Bayer stock.